1[1]Slavin S. Treatment of myeloid leukemia with non-m yeloablative stem cell transplantation:Accomplishments and future goals. The ASH Education program Book, 2000, 81-86.
2[2]Shimoni A, Anderlini P, Andersson B, et al. CD8-depleted donor lymp hocyte (DLI) for the treatment of CML relapse after allogeneic transplant:Long t erm follow up and factors predicting of outcome. Blood,1999, 949:160-161.
3[3]McGlave P B, Ou S X, Wanging W, et al. Unrelated donor marrow transpla ntation for chronic myelogenous leukemia:9 year's experience of the National Mar row Donor Program. Blood, 2000, 95:2219-2220.
4[4]Nagler A, Or R, Naparstek E, et al. Matched unrelated bone marrow tran splantation (BMT) using a non-myeloablative conditioning regimens. Blood, 1998, 92:289-290.
同被引文献8
1Wadhwa J, Szydlo R M, Apperley J F, et al. Factors affecting duration of survival after onset of blastic trans-formation of chronic myeloid leukemia. Blood, 2002,99:2304-2309.
2Deininger M W, Golderman J M, Lydon N, et al. The tyrosine kinase inhibitor CGP571 48B selectively inhibits the growth of BCR-ABL positive cells. Blood, 1997,90:3691-3698.
3Champlin R, Khouri I, Shimoni A, et al. Harnessing graft versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation,an evolving strategy for adoptive immunotherapy. Br J Haematol, 2000, 111:18-29.
4Baker M B, Altman N H, Podack E R, et al. The role of cell-mediated cytotoxicity in acute GVHD after MHC-mediatedbone marrow transplantation in mice.JExp Med, 1996, 183:2645-2656.
5Harris D T, Sakiestewa D, Lyons C, et al. Prevention ofgraft-versus-host disease (GVHD) by elimination of recipi-ent-reactive donor T cells with recombinanttoxins thattargetthe interleukin2 (IL-2) receptor. Bone Marrow Transplantation, 1999, 23:137-144.
6Druker B J. Imatinib Alone and in Combination for Chronic Myeloid Leukemia. Seminars in Hematology,2003, 40:50-58.
7Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem ceil transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998,91:756-763.
8Druker B J, Talpaz M, Resta D J, et al. Effcacy and safety of a speci, c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med,2001, 344:1031-1037.
